MOXI trial—is it time to stop routinely recommending antioxidant therapy to infertile men?

Reflections
Published
Go to the profile of Fertility and Sterility
Fertility and Sterility
Editorial Office, American Society for Reproductive Medicine
MOXI trial—is it time to stop routinely recommending antioxidant therapy to infertile men?
Like

Related Content

Fertility and Sterility
Fertility and Sterility Fertility and Sterility

MOXI trial—is it time to stop routinely recommending antioxidant therapy to infertile men?

Nutraceutical therapy—and more specifically antioxidant supplementation (AoS)—has a special place in male reproductive medicine. Even before DNA fragmentation and reactive oxygen species testing became more widely available, we have been leading our patients to the edge of the tangled forest that is…

Volume 113, Issue 3, Page 542

Author:

Martin Kathrins, M.D.

Abstract:

Reflections on "The effect of antioxidants on male factor infertility: the MOXI randomized clinical trial" by Steiner et al.


Read the full text here.

Go to the profile of Fertility and Sterility
Fertility and Sterility
Editorial Office, American Society for Reproductive Medicine

Fertility and Sterility® is an international journal for obstetricians, gynecologists, reproductive endocrinologists, urologists, basic scientists and others who treat and investigate problems of infertility and human reproductive disorders. 

Please sign in or register for FREE

Your Fertility and Sterility Dialog login information is not the same as your ASRM or EES credentials. Users must create a separate account to comment or interact on the Dialog.

Sign In Register

Recommended Content